Markerless DNA Production via Suppressor tRNA and Nonsense Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA delivery methods, such as adeno-associated virus (AAV) vectors, are limited by the size of DNA constructs they can carry and generate an immune response, while antibiotic resistance markers in DNA vectors are energetically costly and increase vector length, reducing production efficiency.
Innovation Solution
Engineered bacterial strains with nonsense mutations in efflux or import genes and vectors encoding suppressor tRNAs allow for markerless DNA production, enabling efficient and robust microbial growth without antibiotic resistance markers, thus overcoming size limitations and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If antibiotic resistance markers are used in DNA vectors for positive selection, then bacterial cells can be easily selected and maintained, but the vector length increases and metabolic burden on bacteria increases, reducing DNA production efficiency
Solution Approach 1:
The patent removes the antibiotic resistance marker from the DNA vector, extracting the harmful element that caused the contradiction. Instead of using antibiotic resistance for selection, the system uses a different mechanism (nucleotide analog selection) that does not burden the bacterial metabolism or increase vector length, thereby resolving the conflict between ease of selection and DNA production efficiency
Solution Approach 2:
The patent introduces an intermediary substance (nucleotide analog such as 5-fluoroorotic acid or 6-thioguanine) that mediates the selection process. This intermediary allows for positive selection of bacteria containing the DNA vector without requiring antibiotic resistance markers, thus eliminating the metabolic burden while maintaining ease of selection
2Ease of manufacture
If antibiotic resistance markers are used in DNA vectors, then positive selection is convenient, but the total length of the DNA vector increases, reducing overall yield
Solution Approach 1:
The patent extracts the antibiotic resistance marker gene from the DNA vector construction. By removing this unnecessary genetic element, the total vector length is reduced, which directly increases the yield of producible DNA while maintaining the ability to select for bacteria containing the vector through alternative means
3Productivity
If adeno-associated virus vectors are used for DNA delivery, then delivery efficiency is high, but the size of DNA constructs is limited to approximately 4.5 kb
Solution Approach 1:
The patent segments the delivery system by separating the DNA production phase (in bacteria using relaxed plasmids) from the delivery phase (to human cells). This allows the DNA to be produced in a permissive bacterial system without size constraints, then purified and delivered to target cells, thereby overcoming the 4.5 kb limitation of AAV while maintaining efficient delivery
4Productivity
If adeno-associated virus vectors are used for repeated DNA delivery, then initial delivery is effective, but immune response to capsid proteins limits efficiency of future administrations
Solution Approach 1:
The patent creates a copy of the DNA sequence of interest in bacterial plasmids for production, separate from the viral delivery vector. This allows multiple productions of the same therapeutic DNA without repeatedly exposing the patient to the viral capsid, thereby avoiding immune response accumulation while maintaining delivery efficiency across multiple treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of smaller, more efficient DNA vectors that can deliver larger DNA constructs and avoid unwanted immune responses, improving DNA production yield and reducing metabolic burdens on bacterial cells.
Implementation Method 1
the suppressor tRNA comprises an anticodon that is complementary to the STOP codon
Data Source
AI summary
Provided herein are genetically modified microorganisms comprising a nonsense mutation in a gene encoding an efflux pump or import protein, and a vector encoding a suppressor tRNA that enables translation of the efflux pump or import protein, mitigating the effect of the nonsense mutation. Also provided are methods of producing a vector or markerless DNA using the genetically modified microorganisms provided herein.